BACKGROUND: Recent findings, showing the presence of an inflammatory process in the brain of transgenic mice expressing P301S mutated human tau protein, indicate that neuroinflammation may contribute to tau-related degeneration in frontotemporal dementia and parkinsonism linked to chromosome 17 with tau mutations (FTDP-17T). OBJECTIVE: To investigate the occurrence of neuroinflammatory changes in the brain of a patient affected by FTDP-17T associated with the P301S mutation and showing a frontotemporal dementia phenotype as well as in the brain of a patient affected by another FTDP-17T phenotype: multiple system tauopathy with presenile dementia. METHODS: We used immunohistochemical methods to visualize activated microglia, interleukin-1b (IL-1b)-, cyclooxygenase-2 (COX-2)-expressing cells. RESULTS: In the brain of the patient with the P301S mutation, a strong neuroinflammatory reaction was present. Activated microglia/infiltrating macrophages expressing the cluster of differentiation 68 and major histocampatibility complex class II cell surface receptors, encoded by the human leukocyte antigen DP-DQ-DR, were detected in the cortex and hippocampus. IL-1b and COX-2 expression were induced in neuronal and glial cells. These neuroinflammatory changes were different from those observed in the brain of the patient bearing the +3 mutation, where macrophage infiltration was absent, microglial cells displayed an earlier stage of activation and COX-2 was not detected. CONCLUSIONS: Our findings suggest that microglial activation and the production of proinflammatory mediators by phospho-tau-positive neurons and glial cells may differentially contribute to neuronal death and disease progression in neurodegenerative tauopathies.
BACKGROUND: Recent findings, showing the presence of an inflammatory process in the brain of transgenic mice expressing P301S mutated human tau protein, indicate that neuroinflammation may contribute to tau-related degeneration in frontotemporal dementia and parkinsonism linked to chromosome 17 with tau mutations (FTDP-17T). OBJECTIVE: To investigate the occurrence of neuroinflammatory changes in the brain of a patient affected by FTDP-17T associated with the P301S mutation and showing a frontotemporal dementia phenotype as well as in the brain of a patient affected by another FTDP-17T phenotype: multiple system tauopathy with presenile dementia. METHODS: We used immunohistochemical methods to visualize activated microglia, interleukin-1b (IL-1b)-, cyclooxygenase-2 (COX-2)-expressing cells. RESULTS: In the brain of the patient with the P301S mutation, a strong neuroinflammatory reaction was present. Activated microglia/infiltrating macrophages expressing the cluster of differentiation 68 and major histocampatibility complex class II cell surface receptors, encoded by the human leukocyte antigen DP-DQ-DR, were detected in the cortex and hippocampus. IL-1b and COX-2 expression were induced in neuronal and glial cells. These neuroinflammatory changes were different from those observed in the brain of the patient bearing the +3 mutation, where macrophage infiltration was absent, microglial cells displayed an earlier stage of activation and COX-2 was not detected. CONCLUSIONS: Our findings suggest that microglial activation and the production of proinflammatory mediators by phospho-tau-positive neurons and glial cells may differentially contribute to neuronal death and disease progression in neurodegenerative tauopathies.
Authors: H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray Journal: Neurobiol Aging Date: 2000 May-Jun Impact factor: 4.673
Authors: Salvatore Spina; Martin R Farlow; Frederick W Unverzagt; David A Kareken; Jill R Murrell; Graham Fraser; Francine Epperson; R Anthony Crowther; Maria G Spillantini; Michel Goedert; Bernardino Ghetti Journal: Brain Date: 2007-12-07 Impact factor: 13.501
Authors: Jeroen J M Hoozemans; Robert Veerhuis; Ingrid Janssen; Evert-Jan van Elk; Annemieke J M Rozemuller; Piet Eikelenboom Journal: Brain Res Date: 2002-10-04 Impact factor: 3.252
Authors: Nicole Maphis; Guixiang Xu; Olga N Kokiko-Cochran; Shanya Jiang; Astrid Cardona; Richard M Ransohoff; Bruce T Lamb; Kiran Bhaskar Journal: Brain Date: 2015-03-31 Impact factor: 13.501
Authors: Grace M Niziolek; Ryan M Boudreau; Jennifer Baker; Lou Ann Friend; Amy T Makley; Michael J Edwards; Erich Gulbins; Michael D Goodman Journal: J Neurotrauma Date: 2020-05-04 Impact factor: 5.269
Authors: Melissa K Edler; Chet C Sherwood; Richard S Meindl; Emily L Munger; William D Hopkins; John J Ely; Joseph M Erwin; Daniel P Perl; Elliott J Mufson; Patrick R Hof; Mary Ann Raghanti Journal: J Comp Neurol Date: 2018-11-16 Impact factor: 3.215
Authors: Johannes Brettschneider; David J Libon; Jon B Toledo; Sharon X Xie; Leo McCluskey; Lauren Elman; Felix Geser; Virginia M Y Lee; Murray Grossman; John Q Trojanowski Journal: Acta Neuropathol Date: 2012-01-01 Impact factor: 17.088
Authors: Ione O C Woollacott; Jennifer M Nicholas; Carolin Heller; Martha S Foiani; Katrina M Moore; Lucy L Russell; Ross W Paterson; Ashvini Keshavan; Jonathan M Schott; Jason D Warren; Amanda Heslegrave; Henrik Zetterberg; Jonathan D Rohrer Journal: Dement Geriatr Cogn Disord Date: 2020-04-28 Impact factor: 2.959
Authors: Sandra Amor; Laura A N Peferoen; Daphne Y S Vogel; Marjolein Breur; Paul van der Valk; David Baker; Johannes M van Noort Journal: Immunology Date: 2014-06 Impact factor: 7.397